Pandia Health Review: Prescribing Data, Outcomes Signals, and What Women Should Know

What Is Pandia Health and How Does It Work?

Pandia Health positions itself as a women-first telehealth service for birth control and menopause. Founded by OB-GYN Dr. Sophia Yen in 2016, it operates on a cash-pay, subscription-style model where you complete an online questionnaire and a licensed clinician reviews it to prescribe, with medication delivered by mail. The platform does not bill insurance directly, which matters for your out-of-pocket math.

The core workflow is asynchronous: you fill out a health history form, a clinician reviews it, and a prescription is sent to a partnered pharmacy. For some requests, a synchronous video visit is required, particularly for new menopause hormone therapy (HRT) patients or anyone with a complex history.

Pandia Health currently operates in approximately 40 states. Because telehealth prescribing rules differ by state, your eligibility depends on where you are licensed as a patient at the time of the visit, not where you live permanently.

What Conditions and Life Stages Does It Cover?

Pandia Health's stated clinical focus maps to two major life stages:

• Reproductive years: Combined oral contraceptives (COCs), progestin-only pills (POPs), patch, ring, and emergency contraception
• Perimenopause and postmenopause: Systemic estrogen-progestogen therapy and low-dose vaginal estrogen for genitourinary syndrome of menopause (GSM)

The platform does not publicly list services for PCOS-specific management, endometriosis, fertility workup, postpartum care, or thyroid conditions. Women seeking care for any of those diagnoses will need to look elsewhere or supplement with a primary care clinician.

Is Pandia Health Legit? Regulatory and Credentialing Signals

Pandia Health is a real, operational telehealth company with licensed clinicians. That is the baseline. The more useful question is whether its prescribing and oversight practices meet the standard you should expect.

Medical Licensing and Prescriber Credentials

Prescribers on the platform must hold active state medical licenses. Pandia Health employs both physicians and nurse practitioners (NPs). Because the platform uses asynchronous review for most contraception requests, the prescribing clinician typically does not conduct a real-time interview. This is legal in most states but is a structural difference from a synchronous visit where the clinician can ask follow-up questions in real time.

The FDA's guidance on telehealth prescribing makes clear that a valid patient-prescriber relationship must exist before a controlled substance is issued. Hormonal contraceptives and most HRT formulations are not controlled substances, so the threshold for prescribing is lower, but a thorough intake still matters for safety screening.

LegitScript Status

LegitScript is the standard third-party verification body for online pharmacies and telehealth platforms. Pandia Health has been listed in LegitScript's database. Verification status for specific products on the platform can shift, so you should check directly at sign-up. A LegitScript listing means the platform has undergone some degree of compliance review, but it does not constitute a clinical quality endorsement.

BBB Complaints and Rating

As of January 2025, Pandia Health is not accredited by the Better Business Bureau. The BBB profile shows a pattern of complaints concentrated in billing disputes, prescription delays, and difficulty canceling subscriptions. The complaint volume is not unusually high for a telehealth platform of this size, but billing transparency is a real friction point. Several reviewers on the BBB and on Trustpilot report unexpected charges after cancellation.

This is an operational quality signal, not a clinical safety signal, but it matters for your decision. A service that is hard to cancel or opaque about billing can deter women from seeking care when something changes medically, because they fear the administrative headache of adjusting or ending the relationship.

Prescribing Data and Outcomes Signals: What the Evidence Actually Shows

No peer-reviewed outcomes study has been published using Pandia Health's patient population as of January 2025. This is not unique to Pandia Health. Most direct-to-consumer telehealth platforms do not publish clinical outcomes data. The absence of published data is itself a signal: you are relying on platform-level marketing claims and external regulatory records rather than head-to-head trial data.

Here is a framework for interpreting what signals do exist:

Signal 1: Contraception Safety Standards at the Population Level

The contraceptives Pandia Health prescribes are well-studied in the general population. The risk of venous thromboembolism (VTE) with combined oral contraceptives is approximately 3 to 9 per 10,000 woman-years depending on progestogen type, compared with roughly 1 to 5 per 10,000 in non-users. The ACOG Practice Bulletin on combined hormonal contraceptives identifies absolute contraindications that any prescribing clinician must screen for: personal history of VTE, migraine with aura, uncontrolled hypertension (blood pressure consistently above 160/100 mmHg), and active smoking in women over 35.

The clinical question is whether an asynchronous questionnaire screens for these contraindications as reliably as a face-to-face visit. There is no published comparative study on Pandia Health's intake specifically. A 2021 systematic review in Contraception found that telehealth-based contraceptive initiation did not increase adverse events compared with in-person initiation in the studies reviewed, but those studies used a range of telehealth modalities, not all asynchronous.

Signal 2: Blood Pressure Screening Gap

ACOG recommends blood pressure measurement before initiating combined hormonal contraception. ACOG's guidance is explicit: combined estrogen-containing methods should not be used when blood pressure is consistently at or above 160/100 mmHg. Pandia Health asks for self-reported blood pressure on its intake form for combined pill requests.

Self-reported blood pressure is less accurate than a clinic measurement. A 2019 study in Hypertension found that self-measured blood pressure using a home monitor is reasonably reliable when a validated device is used correctly, but a questionnaire asking you to recall a reading is a different situation entirely. If you have not had a blood pressure check recently, do one before starting any estrogen-containing contraceptive, regardless of which platform you use.

Signal 3: Menopause Prescribing Against Society Guidelines

For HRT, the 2023 Menopause Society (NAMS) Position Statement on Hormone Therapy is the governing clinical reference in the United States. It states that for women under 60 or within 10 years of menopause onset with no contraindications, the benefits of systemic HRT generally outweigh the risks for managing vasomotor symptoms. Whether Pandia Health's prescribing aligns with this window-of-opportunity framing is not publicly verifiable from outside the platform.

The Menopause Society position also specifies that women with an intact uterus require progestogen alongside systemic estrogen to protect the endometrium. A telehealth platform prescribing unopposed estrogen to a woman with a uterus would be a serious clinical error. There is no public record indicating Pandia Health has done this systematically, but it is a question worth asking your prescriber directly.

Sex-Specific Pharmacology: Why Your Hormonal Status Changes Everything

Women metabolize many drugs differently than men, and the specific contraceptives and HRT formulations Pandia Health offers are no exception. This is where generic telehealth platforms sometimes fall short: they apply population-level protocols without accounting for where you are in your hormonal life.

Reproductive Years: The Pill and Your Cycle

Combined oral contraceptives suppress the hypothalamic-pituitary-ovarian (HPO) axis. This is the intended mechanism of action, but it also means that cycle-related symptoms you were experiencing before the pill (ovulatory pain, mid-cycle spotting, premenstrual symptoms) may be masked rather than resolved. An asynchronous questionnaire may not tease out whether your reason for requesting the pill is purely contraceptive or also symptom-driven, which would change the ideal formulation choice.

For women with PCOS using combined pills for cycle regulation or androgen control, the choice of progestogen matters. Drospirenone and cyproterone acetate have anti-androgenic properties; levonorgestrel and norethindrone do not. Pandia Health may not offer all progestogen formulations, and the intake questionnaire may not ask about androgen-excess symptoms specifically.

Perimenopause: The Overlap Problem

Perimenopause typically spans 4 to 8 years before the final menstrual period. FSH levels fluctuate widely and are not reliable for diagnosing perimenopause in isolation. During this stage, you may still be ovulating intermittently and therefore still at risk for unintended pregnancy, even if your cycles are irregular.

A telehealth platform needs to distinguish between a perimenopausal woman who needs contraception (and possibly symptom management) and a postmenopausal woman who needs HRT without contraception. These are different clinical situations requiring different prescriptions. If you are 47 with irregular cycles and hot flashes, the intake form should be asking about your last period, cycle variability, and contraceptive needs simultaneously. Whether Pandia Health's form does this comprehensively is worth confirming at intake.

Postmenopause: GSM and Systemic HRT

After menopause, declining estrogen affects the vaginal epithelium, urinary tract, and bone density. Low-dose vaginal estrogen is considered safe for most women, including breast cancer survivors in many cases, because systemic absorption is minimal. Systemic HRT carries a different risk-benefit calculation, particularly for breast cancer risk with estrogen-progestogen combinations used beyond 5 years.

The Women's Health Initiative (WHI) trial, published in JAMA in 2002, found a hazard ratio of 1.26 for invasive breast cancer with conjugated equine estrogen plus medroxyprogesterone acetate after a mean of 5.6 years. Subsequent reanalysis, including data published in JAMA Internal Medicine in 2017, showed that the risk profile differs by HRT formulation, timing, and route. A telehealth platform should be offering individualized counseling on this, not a one-size protocol.

Pregnancy, Lactation, and Contraception: A Required Clinical Section

Hormonal contraceptives are contraindicated during pregnancy. This is unambiguous. If you discover you are pregnant while taking a combined pill, patch, or ring, you should stop immediately. Evidence to date does not suggest that first-trimester exposure to combined hormonal contraceptives causes fetal harm, but continued use is not appropriate and not indicated.

Trying to Conceive

If you are stopping hormonal contraception to try to conceive, most guidelines suggest that fertility returns quickly, often within one to three months, after stopping combined pills. The ACOG Committee Opinion on fertility after discontinuing contraception is consistent with this. A telehealth platform like Pandia Health is not the right venue for preconception counseling or fertility evaluation. You need a reproductive endocrinologist or OB-GYN for that.

Lactation

Estrogen-containing contraceptives may reduce milk supply, particularly in the early postpartum period. ACOG's guidance on postpartum contraception recommends that women who are breastfeeding use progestin-only methods (the mini-pill, progestin IUD, or implant) or non-hormonal methods rather than combined hormonal contraceptives for at least the first 6 weeks postpartum.

If you are in the postpartum period and seeking contraception through Pandia Health, make sure your intake form clearly documents that you are breastfeeding. The progestin-only pill is appropriate in this setting; combined pills are not recommended while exclusively breastfeeding in the first 6 weeks.

Teratogenic Risk with HRT

Standard HRT formulations (estrogen and progestogen) are not approved for use in pregnancy and should not be used. If a perimenopausal woman on HRT becomes pregnant (which can occur if contraception has not been addressed), she should stop HRT immediately and seek OB-GYN care.

Who Pandia Health Is Right For and Who Should Look Elsewhere

Being direct matters here. Pandia Health works well for some women and is not the best fit for others.

Good Fit

• You are in your reproductive years, have no VTE history, no migraine with aura, no uncontrolled hypertension, and want a straightforward combined or progestin-only pill with mail delivery
• You are postmenopausal, have had previous in-person workup, and need a prescription refill for HRT you are already stable on
• You live in a state where local OB-GYN access is limited and you need bridge contraception while establishing with a local provider
• You are comfortable with asynchronous care and self-monitoring (blood pressure, symptom tracking)

Not a Good Fit

• You have migraine with aura: combined estrogen-containing contraceptives are contraindicated per ACOG and WHO Medical Eligibility Criteria, and an asynchronous form may not adequately screen for this
• You are perimenopausal with complex symptoms including mood changes, irregular bleeding, or suspected thyroid dysfunction
• You are postpartum and breastfeeding and need nuanced contraception counseling
• You have a personal or family history of breast cancer requiring individualized HRT discussion
• You have PCOS, endometriosis, or fibroids and need condition-specific management beyond cycle suppression
• You have had a prior thrombotic event

Complaints, Red Flags, and How to Protect Yourself

The BBB complaint pattern for Pandia Health, as of January 2025, clusters around three issues: billing after cancellation, prescription delays, and difficulty reaching customer support. These are operational problems, not clinical safety crises, but they carry real consequences.

A billing dispute that keeps you enrolled when you want to stop means you may delay seeking care elsewhere. A prescription delay in contraception has a concrete clinical consequence: a gap in protection that can result in unintended pregnancy.

Practical Steps Before You Sign Up

1. Screenshot your cancellation confirmation and save the date. Use a credit card rather than a debit card so you have chargeback rights if billing errors occur.
2. Ask specifically which prescriber will review your case and what their credentials are before you pay.
3. If you are switching from another contraceptive method or starting HRT for the first time, confirm whether a video visit is required at Pandia Health for your specific situation.
4. Cross-reference any HRT prescription you receive against the 2023 NAMS Position Statement on Hormone Therapy to confirm it aligns with current evidence.

Evidence Gaps and What Is Extrapolated

Women have been under-represented in drug trials across the board. Most contraceptive trial data comes from reproductive-age women in relatively good health, which means generalizability to women with comorbidities (diabetes, obesity, autoimmune conditions) is imperfect. HRT data from the WHI has been criticized for enrolling an older, higher-risk cohort than the women most likely to use HRT today.

For Pandia Health specifically, there is no published comparative effectiveness data, no outcomes registry, and no publicly available adverse event reporting beyond what surfaces in FDA MedWatch and BBB records. The FDA MedWatch program collects adverse event reports from patients and clinicians, but these are voluntary and underrepresent real-world event rates.

This is not a reason to avoid telehealth for contraception or HRT. It is a reason to go in with clear expectations: you are receiving care based on validated clinical protocols applied to your self-reported history. The quality of that care depends heavily on how thorough the intake is and how available your prescriber is for follow-up questions.

"The asynchronous model is efficient and removes real access barriers, but it shifts more of the safety burden onto the patient to report accurately and to flag changes in her health history," says WomanRx reviewer Elena Vasquez, MD. "For a healthy 28-year-old who has been on the pill before, that is a reasonable trade-off. For a 51-year-old with hot flashes and an irregular cycle, I would want a synchronous visit before starting any systemic hormone therapy."

Pandia Health vs. Other Telehealth Platforms: A Structural Comparison

Pandia Health's narrow focus on contraception and menopause distinguishes it from broader women's health telehealth platforms (such as Wisp, Nurx, or Hey Jane). That focus can be a strength if your needs are exactly within that scope. It becomes a limitation if your reproductive health is more complex.

No head-to-head clinical trial compares outcomes between Pandia Health and competitors. What can be compared structurally:

| Feature | Pandia Health | What to Look For Elsewhere | |---|---|---| | Menopause HRT | Yes, systemic and vaginal | NAMS-certified practitioner on staff | | PCOS management | Not listed | Platforms with reproductive endocrinology access | | Postpartum care | Not listed | ACOG-aligned postpartum telehealth | | Synchronous option | Available for complex cases | Default for first HRT visit | | Insurance billing | No | Some platforms accept major insurers | | Outcomes data published | None as of Jan 2025 | Ask any platform for this |